Thank you for reading

Exciting news on clinical trials

• Towards a CRISPR-cure for Sickle Cell Disease and β-thalassemia. Vertex and CRISPR Therapeutics have announced »remarkable and unprecedented data« from landmark CRISPR-Cas9 gene-editing clinical trial. The new data show patients don't need blood-transfusions up to 15 months after the therapy began and are symptom-free. CRISPR continues to live up to the hype, but the competition is getting hot.

• And while on the topic of CRISPR clinical trials, a new study has just been added to our comprehensive overview. It's a study using CRISPR genome-edited off-the-shelf (allogeneic) T cells to target CD70-antigen-bearing kidney cancer cells. The study is sponsored by CRISPR Therapeutics and marks a transition from hematologic to solid tumours.

Thank you for now - more great reads are on the way!

And if you have questions or suggestions, you can reach out to us directly at editor@crisprmedicinenews.com. We love hearing from readers!

(c; Rasmus

p.s. You can follow CRISPR Medicine News on Twitter and LinkedIn. If someone forwarded this email to you, you can sign up for our newsletter yourself here.